Complete report $1,850. Individual company assessments $250. The companies analyzed in this report include BASF, Cambrex, Clariant, DowPharma, DSM, Evonik, Lanxess, Lonza, Novasep, and Rhodia. For each company, the report provides insightful strategic assessments, including: • Specific business, new product development and marketing strategies. • Strengths and weaknesses. • Anticipated acquisitions, joint ventures and divestitures. Contains 50 pages
|